While prior research had suggested that exercise could improve the quality of life for cancer patients and alleviate chemotherapy side effects, new evidence now underscores its role in boosting survival rates. A groundbreaking study presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirms this transformative potential.

The Challenge trial, spearheaded by the Canadian Cancer Trials Group, uniquely investigates whether exercise can function as a cancer treatment on par with surgery, medication, or radiotherapy. Over 17 years, from 2009 to 2024, the study tracked 889 high-risk colon cancer patients in stages II and III. Post-surgery and chemotherapy, participants were divided: half engaged in a structured exercise regimen, while the remainder received educational materials.

The exercise program aimed to elevate aerobic physical activity. Participants in the exercise group adhered to a regimen of brisk walking or moderate jogging, accumulating 45 to 60 minutes of activity three to four times a week over three years.

After an eight-year follow-up, results revealed a 90% survival rate in the exercise group, compared to 83% in the educational group, with a 37% reduction in mortality risk among those who exercised. Kerry Courneya, a leading researcher from the University of Alberta, emphasizes that exercise has transcended its role as a quality-of-life intervention to become an essential treatment for colon cancer.

Chris Booth, co-coordinator of the study published in the New England Journal of Medicine, clarifies that while exercise is not a substitute for surgery or chemotherapy, it should be integrated as a vital component of cancer treatment. The study advocates for the inclusion of trainers within medical teams to facilitate habit changes crucial for improving survival outcomes.

Integrating exercise into post-surgery and chemotherapy treatment involved guidance from physiotherapists or kinesiologists, allowing participants to choose moderate-intensity activities. Booth highlights that the benefits of exercise are comparable to, or even exceed, those of certain medications, enhancing chemotherapy's effectiveness.

For the successful implementation of such treatment regimens, it is imperative to employ professionals capable of crafting personalized exercise programs and providing continuous monitoring. Terri Swain-Collins, a trial participant, noted the critical role of personalized guidance in maintaining exercise adherence.

Mikel Izquierdo, a professor at the Public University of Navarra, describes the study as a pivotal moment in cancer treatment, establishing a causal link between exercise and improved disease-free survival and reduced mortality. He argues for revising clinical guidelines to incorporate exercise as a treatment modality, akin to pharmacological interventions.

Izquierdo, instrumental in drafting guidelines for exercise as medicine for the elderly, warns that exercise prescriptions must be tailored and dosed appropriately, akin to drugs. He calls for systemic readiness to adopt this metabolic immunotherapy, noting the need for investment in trained personnel and infrastructure.

Scientific evidence supporting the benefits of exercise in cancer has been accumulating. Several studies suggest that regular aerobic exercise significantly reduces anxiety, depression, and fatigue associated with cancer and its treatments. Although not initially designed to validate exercise as a cancer therapy, these findings consistently link regular physical activity with increased survival rates in colon, prostate, and breast cancers. This newly published study introduces a promising, low-risk therapeutic avenue for cancer management, albeit requiring a comprehensive implementation strategy at scale.